From the Sept quarterly - they has $10.5m cash. Now receiving,$6.9m in R&D, with Operating outflows as per previous quartet of say $5m (which is extremely high, considering there was $1.6m in revenue).
They still should have over $12m in cash at end of Dec. So money should not be an issue.
A note from the Sept quarterly, they have been in dialogue with the FDA and provided responses to questions.
Hopefully the placement and raise is to coincide with FDA clearance, and to ramp up roll-out of units in every state of the US.
Ann: Quarterly update and Appendix 4C, page-14
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
72.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $156.0M | |||
| Open | High | Low | Value | Volume |
| 72.5¢ | 72.5¢ | 71.5¢ | $55.75K | 77.21K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 36846 | 71.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 74.0¢ | 20000 | 1 |
View Market Depth
| Last trade - 15.53pm 21/06/2024 (20 minute delay) ? |
| GSS (ASX) Chart |